TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03548129

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre-treatment Urine Culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pre-treatment Urine Culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobial sensitivity testing
Description: Susceptibility of urinary pathogens to various antimicrobials

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Post-treatment urine culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Post-treatment urine culture
Description: Mid-stream urine sample will be cultured and number of CFU per mL will be determined.
Study: NCT04621578

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)
Description: Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANS 100B stimulator (4 conductors, 8 electrodes; Jisheng Co., Nanjing, China)
Description: Stimulation sites: Mastoid area on the contralateral side of the operation, Fengchi acupoint on the contralateral side of the operation, and Neiguan acupoints on both sides.~Timing of stimulation: In postanesthesia care unit (PACU) after extubation, 6 hours, 24 hours, 48 hours, and 72 hours after returning to the ward. 30-minutes treatment for each time-point.
Study: NCT01624753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: confocal microscopy
Description: During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
Study: NCT01943760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tramadol
Description: The volume of the solution was adequate to maintain the concentration of 2% tramadol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol
Description: The volume of the solution was adequate to maintain the concentration of 2% tramadol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% saline
Study: NCT02961686

Intervention type: RADIATION
Intervention: Patients affected by prostate cancer
Description: Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
Study: NCT03916471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Solyx™ SIS System
Description: Single-incision sling system
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine
Study: NCT03916471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Obtryx™ II System (Halo)
Description: Transobturator Mid-urethral Sling System
Study: NCT04144855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3474 injection
Description: This is a kind of heat shock protein (HSP90) inhibitor.
Study: NCT03309787

Intervention type: BEHAVIORAL
Intervention: eHealth
Description: Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring

Intervention type: BEHAVIORAL
Intervention: eHealth
Description: Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring

Intervention type: BEHAVIORAL
Intervention: eHealth
Description: Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
Study: NCT02951390

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-definition white-light endoscopy
Description: The intervention is do not perform chromoendoscopy
Study: NCT01933165

Intervention type: DEVICE
Group type: OTHER
Intervention: LipiView
Study: NCT04687605

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary hypercapnia
Description: Temporary daily hypercapnia for 2 hours between day 4 and 14 after SAH
Study: NCT03918785

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice germ
Description: 25 g twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat-based supplement
Description: 25g twice a day.
Study: NCT03921138

Intervention type: OTHER
Intervention: Histopathologic tube anomalies
Description: Assessment of prevalence of histopathologic tube anomalies (Serous Tubal Intraepithelial Carcinoma (STIC) or tumor protein 53 (p53) lesion)
Study: NCT01592409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: delta-9-tetrahydrocannabinol
Description: A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
Study: NCT01951690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defactinib (VS-6063)
Study: NCT03072641

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProBion Clinica
Study: NCT01175278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebral Augmentation with Balloon Kyphoplasty
Description: Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Treatment
Description: Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine
Study: NCT01591733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: Up to Eight-14 day cycles
Study: NCT05992272

Intervention type: BEHAVIORAL
Intervention: No-go Simon task
Description: Will be used to measure interference at the response level and response inhibition. We will show arrows either pointing to the left or right. The arrow can either be shown on the left or the right side of the display. In congruent trials, direction and position are the same, whereas they differ in incongruent trials. Participants have to indicate the direction of the arrow and ignore the position.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task
Description: Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task
Description: Will be used to examine inhibitory control. The participants tap the left and right side of the screen to smash two falling fruits. When the fruits pass two circles, subjects are required to tap both sides of the screen. In stop trials one of the fruits turns brown (rotten), indicating the corresponding side of the screen should not be tapped.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
Study: NCT02310828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetium
Description: Capsule for oral administration contains L-cysteine 100mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule matching Acetium for oral administration.
Study: NCT05992272

Intervention type: DIAGNOSTIC_TEST
Intervention: blood samples
Description: for genetic and epigenetic testing, especially for exploratory outcome prediction using polygenic risk scores.
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: CSD1904-01, a nicotine pouch, 2 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: CSD1904-02, a nicotine pouch, 4 mg nicotine
Study: NCT03866252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LSD
Description: LSD administration per os
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
Study: NCT05992272

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires for chronic stress
Description: * Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic

Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaires for chronic stress
Description: * Perceived Stress Scale~* Social Readjustment Rating Scale~* Trier Inventory for the Assessment of Chronic
Study: NCT01591733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally, for 10 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short Course Radiation
Description: Five or ten days
Study: NCT04372290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: CSD1904-02, a nicotine pouch, 8 mg nicotine (simultaneous use of two 4 mg nicotine pouches)
Study: NCT00896194

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Treatment
Description: SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Standard Behavioral Intervention + Self-Efficacy
Description: This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
Study: NCT02589158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evotaz
Description: All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezolsta
Description: All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
Study: NCT00643214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetrix
Description: Twice daily topical application

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tetrix
Description: Twice daily topical application
Study: NCT05992272

Intervention type: DIAGNOSTIC_TEST
Intervention: hair samples
Description: Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.

Intervention type: DIAGNOSTIC_TEST
Intervention: hair samples
Description: Hair cortisol measurement (3 cm hair segments) will be used to assess chronic stress.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Assessing acute stress effects in AUD.

Intervention type: DIAGNOSTIC_TEST
Intervention: saliva samples
Description: Assessing acute stress effects in AUD.

Intervention type: DIAGNOSTIC_TEST
Intervention: EMA assessment
Description: We will use smartphones with additional mobile sensors (wearables), which will be used to measure physical activity, data on location (GPS), geolocation-based triggering of e-Diaries, self-reported stress reactivity, cue exposure (encounters with drug-related stimuli in real life), drug craving, impulsivity and drug consumption (priming doses, binges and continuous use of all drugs of abuse).

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical diagnostic
Description: SKID-I Interview neurocognitive and psychopathological testing

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical diagnostic
Description: SKID-I Interview neurocognitive and psychopathological testing
Study: NCT02474810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase for CVC dysfunction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase for CVC dysfunction.
Study: NCT00674921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cotrimoxazole
Description: cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch, magnesium stearate, sodium lauryl sulphate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: starch, magnesium stearate, sodium lauryl sulphate
Study: NCT01591733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: 1-4 weeks after completion of capecitabine therapy
Study: NCT01576484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matched to Alirocumab
Description: Placebo matched to alirocumab was supplied in a pre-filled syringe and administered subcutaneously (SC) in the abdomen, thigh, or outer upper arm; REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
Study: NCT00624026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine-HCl
Description: 20 mg per day (once daily)
Study: NCT01918644

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study: NCT02219152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Study: NCT01918644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo definitive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT04226664

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Although there may be slight variation by centre, Gastric Bypass generally involves creation of a 30-50 cc stomach pouch, which is anastamosed with a Roux limb of jejunum 75-100 cm in length and a biliary limb of 20-30 cm in length. The operation creates a small gastric pouch, with nutrients bypassing the duodenum and proximal jejunum. Sleeve Gastrectomy involves decreasing the size of the stomach to approximately 15% of its original size by resecting a large portion of the stomach along the greater curvature.
Study: NCT01720550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 500 mg
Description: PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus Polysaccharides 250 mg
Description: PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
Study: NCT04025359

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol 2.5 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: Dronabinol 5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04482400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2
Description: 8 week sedentary reduction program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MyKneeGuide
Description: 8 week surgery recovery education program
Study: NCT02219152

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT00470015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: 1000 mcg; Day 1 of a 21 day cycle x 4
Study: NCT03866252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: LSD administration per os
Study: NCT01266434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: 10 mg once daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 10 mg once daily for 8 weeks
Study: NCT00470015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-2
Description: 0.5x10\^6/m\^2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100 antigen
Description: 1000 mcg; Day 1 of a 21 day cycle x 4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 300mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1a peptide
Description: 1000 mcg; Day 1 of a 21 day cycle x 4
Study: NCT01266434

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B1-6-12
Description: 1 tablet once daily for 8 weeks